Meningioma Clinical Trials in New York, New York

6 studies are recruiting for meningioma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

   The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan-Kettering Cancer Center, New York, New York

   Locations

   17 in total

   Run by

   Exelixis

   See if you can join NCT07428616 on ClinicalTrials.gov

2. Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

   This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated progressive tumors of vestibular schwannomas (VS), non-vest…

   Stage

   Phase 2

   Ages

   12 and older

   Site

   New York University Langone Medical Center, New York, New York

   Locations

   6 in total

   Run by

   Scott R. Plotkin, MD, PhD

   See if you can join NCT04374305 on ClinicalTrials.gov

3. A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

   This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   NYU- Langone Health, New York, New York

   Locations

   5 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT07533942 on ClinicalTrials.gov

4. Cabozantinib for Patients With Recurrent or Progressive Meningioma

   A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   3 in total

   Run by

   Baptist Health South Florida

   See if you can join NCT05425004 on ClinicalTrials.gov

5. Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE

   The study team hypothesizes that it is feasible to intraoperatively detect tumor following [CU64]DOTATATE injection using the gamma probe device.

   Stage

   Phase 4

   Ages

   18 to 99

   Site

   New York-Presbyterian/Weill Cornell Medical Center, New York, New York

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT06377371 on ClinicalTrials.gov

6. 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

   The study population consists of patients who undergo resection for somatostatin receptor-positive (SSTR-positive) CNS tumors, focusing on meningioma, and including esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma, and SSTR-positive systemic cancers metasta…

   Stage

   Phase 4

   Ages

   18 to 100

   Site

   Weill Cornell Medicine, New York, New York

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT04081701 on ClinicalTrials.gov